ORIC Pharmaceuticals Presents Rinzimetostat's Potential in Prostate Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
ORIC Pharmaceuticals "announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research Annual Meeting highlighting the potential of rinzimetostat. or ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer. The posters can be found in the publication section of ORIC's website here." "Our research continues to show the therapeutic potential of PRC2 inhibition across the prostate cancer disease spectrum, by reducing tumor adaptability and sustaining the benefit derived from androgen-receptor targeted therapies," said Lori Friedman, PhD, chief scientific officer. "Additionally, our preclinical studies reveal that targeting PRC2 via EED has potential advantages over targeting EZH2, which, together with the clinical data generated to date, furthers our conviction that rinzimetostat is a potential best-in-class PRC2 inhibitor."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.450
Low
15.00
Averages
19.60
High
25.00
Current: 8.450
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Stock Price Plunge: Following ORIC's announcement that its prostate cancer treatment rinzimetostat (ORIC-944) is not as effective as expected, the stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting market disappointment in its product prospects.
- Potential Legal Action: Investors are advised to contact Pomerantz LLP regarding the possibility of joining a class action lawsuit, which could result in significant financial liabilities for the company, further impacting its financial health.
- Reputation Damage: The ongoing investigation and stock price decline have severely damaged ORIC's market reputation, potentially affecting its future financing and business development plans.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of ORIC Pharmaceuticals investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which negatively impacted market confidence.
- Significant Stock Price Drop: Following this news, ORIC's stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating investor concerns regarding the company's future prospects.
- Potential Legal Action: Pomerantz LLP advises investors to contact their attorneys to join a possible class action lawsuit, highlighting the legal risks the company faces, which may affect future shareholder trust and market performance.
See More
Wall Street's Latest Upgrade Calls Overview
- RXO Upgrade: Stifel upgraded RXO from hold to buy, citing a favorable market setup emerging into the latter half of 2026, particularly at the intersection of improving brokerage fundamentals and unique idiosyncratic levers, indicating potential growth opportunities.
- Cisco Rating Boost: HSBC upgraded Cisco to buy from hold following the company's recent earnings report, raising the price target from $77 to $137, reflecting strong momentum in AI infrastructure and improved earnings visibility.
- Arista Networks Upgrade: Raymond James upgraded Arista Networks from market perform to outperform, anticipating improved sales growth in 2027 and beyond, particularly as the company expands into AI backend and campus applications, enhancing its market share.
- Dell Reiteration: Morgan Stanley reiterated its overweight rating on Dell, raising the price target from $205 to $280, expecting the company to raise its FY27 earnings guidance again, although supply visibility still needs to catch up with the high demand outlook for AI servers.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- Stock Price Plunge: Following the March 31, 2026, announcement regarding the effectiveness of ORIC's prostate cancer treatment rinzimetostat (ORIC-944), which fell short of expectations, the stock price plummeted by 41% to close at $7.48 per share, reflecting market disappointment in the product's competitiveness.
- Potential Legal Action: The investigation may lead to a class action lawsuit, with investors encouraged to contact Pomerantz LLP, indicating a significant loss of confidence in the company's future performance, which could impact its financing capabilities and market reputation.
- Historical Context: Pomerantz LLP is a prominent firm in the securities class action field, established over 85 years ago, having recovered millions in damages for victims, demonstrating its strong commitment to protecting investor rights.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of ORIC Pharmaceuticals, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting the firm's commitment to protecting investor rights.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may undermine market confidence.
- Significant Stock Price Drop: Following this announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting investor concerns about the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP is a prominent firm in securities class action litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud, demonstrating its authority and influence in the legal field.
See More
Pomerantz Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating ORIC Pharmaceuticals and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may impact its market competitiveness.
- Significant Stock Price Drop: Following this announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating market concerns regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, recognized for its expertise in securities class actions, may provide legal support to affected investors, further exacerbating ORIC's legal and financial risks.
See More
Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Stock Price Plunge: Following ORIC's announcement that its prostate cancer treatment rinzimetostat (ORIC-944) is not as effective as expected, the stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting market disappointment in its product prospects.
- Potential Legal Action: Investors are advised to contact Pomerantz LLP regarding the possibility of joining a class action lawsuit, which could result in significant financial liabilities for the company, further impacting its financial health.
- Reputation Damage: The ongoing investigation and stock price decline have severely damaged ORIC's market reputation, potentially affecting its future financing and business development plans.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of ORIC Pharmaceuticals investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which negatively impacted market confidence.
- Significant Stock Price Drop: Following this news, ORIC's stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating investor concerns regarding the company's future prospects.
- Potential Legal Action: Pomerantz LLP advises investors to contact their attorneys to join a possible class action lawsuit, highlighting the legal risks the company faces, which may affect future shareholder trust and market performance.
See More
Wall Street's Latest Upgrade Calls Overview
- RXO Upgrade: Stifel upgraded RXO from hold to buy, citing a favorable market setup emerging into the latter half of 2026, particularly at the intersection of improving brokerage fundamentals and unique idiosyncratic levers, indicating potential growth opportunities.
- Cisco Rating Boost: HSBC upgraded Cisco to buy from hold following the company's recent earnings report, raising the price target from $77 to $137, reflecting strong momentum in AI infrastructure and improved earnings visibility.
- Arista Networks Upgrade: Raymond James upgraded Arista Networks from market perform to outperform, anticipating improved sales growth in 2027 and beyond, particularly as the company expands into AI backend and campus applications, enhancing its market share.
- Dell Reiteration: Morgan Stanley reiterated its overweight rating on Dell, raising the price target from $205 to $280, expecting the company to raise its FY27 earnings guidance again, although supply visibility still needs to catch up with the high demand outlook for AI servers.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- Stock Price Plunge: Following the March 31, 2026, announcement regarding the effectiveness of ORIC's prostate cancer treatment rinzimetostat (ORIC-944), which fell short of expectations, the stock price plummeted by 41% to close at $7.48 per share, reflecting market disappointment in the product's competitiveness.
- Potential Legal Action: The investigation may lead to a class action lawsuit, with investors encouraged to contact Pomerantz LLP, indicating a significant loss of confidence in the company's future performance, which could impact its financing capabilities and market reputation.
- Historical Context: Pomerantz LLP is a prominent firm in the securities class action field, established over 85 years ago, having recovered millions in damages for victims, demonstrating its strong commitment to protecting investor rights.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of ORIC Pharmaceuticals, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting the firm's commitment to protecting investor rights.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may undermine market confidence.
- Significant Stock Price Drop: Following this announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting investor concerns about the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP is a prominent firm in securities class action litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud, demonstrating its authority and influence in the legal field.
See More
Pomerantz Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating ORIC Pharmaceuticals and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may impact its market competitiveness.
- Significant Stock Price Drop: Following this announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating market concerns regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, recognized for its expertise in securities class actions, may provide legal support to affected investors, further exacerbating ORIC's legal and financial risks.
See More
